Real-World Evidence on the Use of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Upadacitinib treatment in a real-world difficult-to-treat atopic dermatitis patient cohort
J Eur Acad Dermatol Venereol 2023 Oct 21;[EPub Ahead of Print], AR Schlösser, N Boeijink, J Olydam, TEC Nijsten, D HijnenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.